Skip to Main Content

Paper Details

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Cancer Discov
381
2014
BRAF, BRAF-, BRAF-mutant melanoma, ERK, MAP kinase, MAP-ERK kinase (MEK)1, MAPK, MEK, MEK2, MEK2 kinases, MEK2(Q60P), Q60P, RAF, dabrafenib, drug, extracellular signal-regulated kinase, mitogen-activated protein kinase, patients, trametinib, tumor, tumors
Author NameAffiliation
Nikhil WagleDana-Farber Cancer Institute 2Department of Medicine, Brigham and Women's Hospital 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston 4Broad Institute of Harvard and MIT and 5Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT)
Nikhil WagleDana-Farber Cancer Institute 2Department of Medicine, Brigham and Women's Hospital 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston 4Broad Institute of Harvard and MIT and 5Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT)
  • 1 - 2

Datasets

Release 1.2